Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gemina Laboratories Ltd. C.GLAB

Alternate Symbol(s):  GLABF

Healthcare Diagnostics & Research
Gemina Laboratories Ltd. is a Canada-based biosensor and diagnostic company with a transformative, patented, proprietary chemistry that powers testing platforms for a range of pathogens that affect human health and wellness. The Company operates in the in vitro diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. Its development pipeline includes platforms for the... see more

Recent & Breaking News (CSE:GLAB)

Gemina Laboratories Announces Private Placement

Accesswire 7 days ago

Gemina Laboratories Strategic Update

Accesswire July 10, 2024

Gemina Laboratories Commences Trading on the OTCQB Market in the United States

Accesswire June 20, 2024

Gemina Labs Announces Addition to its IP Portfolio

Accesswire April 9, 2024

Gemina Laboratories Sign First Strategic License Agreement

Accesswire April 2, 2024

Gemina Labs Strategic Update: Focusing on Respiratory Infections and Strategic Partnerships

Accesswire March 21, 2024

Gemina Announces Closing of $910,000 Convertible Note Financing

Accesswire March 19, 2024

Gemina Labs Ltd Appoints Stifel as Financial Advisor

Accesswire November 6, 2023

Canadian Securities Exchange Reports August 2023 Performance Figures

Newsfile September 19, 2023

Gemina Laboratories Announces Major Breakthrough in Environmentally Friendly Lateral Flow Test Design by Removing the Requirement for Nitrocellulose

Accesswire July 25, 2023

Gemina Laboratories to Participate in Poster Session at American Association of Clinical Chemistry Annual Scientific Meeting

Accesswire June 15, 2023

Gemina Laboratories and ReadyGo Diagnostics Achieve Mycobacterium Tuberculosis Diagnosis in Saliva

Accesswire June 5, 2023

Gemina Labs Antibody Immobilization Chemistry Platform Demonstrates Major Lateral Flow Assay Performance Improvement

Accesswire May 17, 2023

Gemina Laboratories to Host Investor Webinar on March 30, 2023

Accesswire March 27, 2023

Gemina Labs Appoints Diagnostic Strategist Martha Najib to the Board

Accesswire March 7, 2023

Gemina Labs Announces Appointment of Healthcare Industry Leader Dr. Bola Grace to The Board of Directors

Accesswire January 25, 2023

Gemina Labs Appoints Top Ranked UK Analyst and Scientist, Dr. Stefan Hamill as Vice President, Strategy

Accesswire January 23, 2023

Gemina Labs Strategic Update: Respiratory Infections the Immediate Focus and New Strategic Partnerships on the Horizon

Accesswire January 10, 2023

Gemina Labs Completes Influenza A/B Diagnostic Test Prototype

Accesswire January 6, 2023

Gemina Labs Appoints Dr Michael Shannon as Chair of Clinical Advisory Board

Accesswire December 20, 2022